ClinicalTrials.gov Pharma Pipeline Monitor

Track every FDA-regulated clinical trial worldwide. Filter by disease, drug, sponsor, phase, status, or country. Free official NIH/NLM API. No key required.

This actor pulls directly from ClinicalTrials.gov API v2 — the NIH/NLM registry of all FDA-regulated clinical studies globally. Every Phase 1/2/3/4 trial, every sponsor (Pfizer, Moderna, Eli Lilly, tiny biotech startups), every condition. Used by pharma competitive intelligence teams, biotech investors, patient recruitment firms, and M&A due diligence.

What you actually get (verified on real trials)

Tested against real Phase 3 trials in high-value therapeutic areas:

Eli Lilly Phase 3 pipeline

NCT	Drug	Indication	Enrollment	Sites
NCT05508789	Donanemab (LY3002813)	Alzheimer's disease	1,500	141
NCT06292013	Lepodisiran Sodium	Atherosclerotic cardiovascular disease	17,300	932
NCT07369011	Eloralintide (LY3841136)	Sleep apnea + obesity	800	122
NCT06890598	Olomorasib (LY3537982)	Non-small cell lung cancer	700	354
NCT07222137	Baricitinib (LY3009104)	Type 1 diabetes delay	150	107

Active CAR-T lymphoma trials (global)

NCT	Sponsor	Drug	Indication	Sites
NCT05641428	University Medical Center Groningen	ARI-0001 vs Axi-cel	DLBCL / NHL	7
NCT07523555	Beijing Biotech	CD19/CD22, CD19/CD20, BCMA/CD19 dual-CAR-T	B-cell malignancies	1
NCT07022964	Beijing GoBroad Hospital	CD5 CAR-T	T-cell lymphomas	3

Each row includes:

• NCT ID, brief title, official title, acronym
• Status (RECRUITING, ACTIVE_NOT_RECRUITING, COMPLETED, TERMINATED, etc.)
• Phase (EARLY_PHASE1, PHASE1, PHASE2, PHASE3, PHASE4, NA)
• Study type, primary purpose, allocation, masking
• Lead sponsor + class (INDUSTRY, NIH, OTHER) + collaborators
• Enrollment count (actual/estimated)
• Conditions array, keywords array
• Interventions array with type/name/description
• Dates: study start, primary completion, completion (all with type = actual/estimated/anticipated)
• Eligibility criteria: age range, sex, healthy volunteers
• Principal investigators (names + affiliations) — optional
• Study locations (facility, city, state, country, status) — optional
• Countries list (for quick geographic view)
• Direct link to ClinicalTrials.gov

Why this matters

Clinical trials are where $800 billion of global pharma R&D spending flows every year. Knowing who is testing what, in what phase, with what outcomes — that's the foundation of the entire pharmaceutical industry's competitive landscape.

Who pays for clinical trial data

• Biotech analysts and investors — predict which drugs will win FDA approval based on trial progression
• Big Pharma competitive intel — track rival Phase 2/3 trials that could disrupt your franchise
• Patient recruitment firms — match patients to eligible trials (companies like Tempus, Flatiron Health, TrialBee make $$)
• Clinical site selection firms — find active investigators and hospitals to recruit as trial sites
• M&A due diligence — assess a target biotech's pipeline value
• KOL (key opinion leader) identification — find principal investigators leading important trials
• Protocol design research — benchmark similar trial endpoints, sample sizes, durations
• FDA regulatory affairs — track competitors' FDA interactions

Commercial alternatives and pricing

• Citeline Trialtrove: $25,000-100,000+/year (the industry gold standard)
• GlobalData Clinical Trials: $30,000+/year
• BioPharma Catalyst: $1,500-5,000/year
• Evaluate Pharma: $50,000+/year
• IQVIA Clinical Trials Intelligence: enterprise pricing
• TrialSetup by Veeva: enterprise pricing
• Clinpipe: $500-2,000/month

This actor delivers the same raw clinical trial data (sourced from the SAME public API) with per-event pricing.

Therapeutic area examples

Common queries this actor handles:

Obesity / GLP-1 weight loss drugs (Ozempic-competitor landscape):

{
  "intervention": "GLP-1",
  "condition": "obesity",
  "phases": ["PHASE3"],
  "statuses": ["RECRUITING", "ACTIVE_NOT_RECRUITING"]
}

Alzheimer's disease (post-Aduhelm/Leqembi/Donanemab era):

{
  "condition": "Alzheimer",
  "phases": ["PHASE2", "PHASE3"]
}

KRAS inhibitors (post-sotorasib cancer boom):

{
  "intervention": "KRAS",
  "phases": ["PHASE1", "PHASE2", "PHASE3"],
  "statuses": ["RECRUITING"]
}

CAR-T cell therapy:

{
  "intervention": "CAR-T",
  "phases": ["PHASE2", "PHASE3"]
}

Moderna mRNA pipeline:

{
  "sponsors": ["Moderna"],
  "phases": ["PHASE2", "PHASE3"]
}

CRISPR gene editing:

{
  "intervention": "CRISPR",
  "phases": ["PHASE1", "PHASE2"]
}

How to use

1. Click Try for free (or Start)
2. Enter condition (disease name) and/or intervention (drug name) — at least one recommended
3. Optionally add sponsors to focus on specific companies
4. Optionally filter by phases (PHASE1, PHASE2, PHASE3, PHASE4) or statuses
5. Set maxResults (default 50, up to 10,000)
6. Toggle includeInvestigators / includeLocations based on your use case
7. Click Start

Output

{
    "nctId": "NCT05508789",
    "briefTitle": "A Study of Donanemab in Participants With Alzheimer's Disease Detected by Plasma Biomarkers",
    "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of Donanemab in Participants With Preclinical Alzheimer's Disease",
    "acronym": "TRAILBLAZER-ALZ 3",
    "status": "ACTIVE_NOT_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": ["PHASE3"],
    "primaryPurpose": "TREATMENT",
    "interventionModel": "PARALLEL",
    "allocation": "RANDOMIZED",
    "maskingType": "QUADRUPLE",
    "leadSponsor": "Eli Lilly and Company",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "enrollmentCount": 1500,
    "enrollmentType": "ACTUAL",
    "conditions": ["Alzheimer Disease", "Dementia"],
    "keywords": ["Preclinical", "Plasma Biomarkers", "Amyloid"],
    "interventions": [
        { "type": "DRUG", "name": "Donanemab", "description": "..." },
        { "type": "DRUG", "name": "Placebo", "description": "..." }
    ],
    "interventionNames": ["Donanemab", "Placebo"],
    "startDate": "2021-07-13",
    "primaryCompletionDate": "2027-01-17",
    "completionDate": "2027-01-17",
    "eligibilityCriteria": "...",
    "minimumAge": "55 Years",
    "maximumAge": "80 Years",
    "sex": "ALL",
    "healthyVolunteers": false,
    "investigators": [
        { "name": "John Doe, MD", "role": "STUDY_DIRECTOR", "affiliation": "Eli Lilly" }
    ],
    "locationCount": 141,
    "countries": ["United States", "Canada", "United Kingdom"],
    "ctGovUrl": "https://clinicaltrials.gov/study/NCT05508789",
    "extractedAt": "2026-04-16T01:00:00.000Z"
}

Pricing

• Actor start: $0.05 per run
• Per trial extracted: $0.01 per trial

Example costs:

• Pull Pfizer's Phase 3 pipeline (~50 trials) → $0.55
• Full cancer Phase 3 pipeline across all sponsors (~800 trials) → $8.05
• Weekly monitoring of 10 biotech companies' trials → ~$5/month
• Monthly comprehensive pull of all 500k+ trials → $5,000 (still cheaper than one Citeline seat)

For comparison: Citeline Trialtrove is $25-100k/year. BioPharma Catalyst is $1,500-5,000/year.

Honest limitations

• Not real-time. ClinicalTrials.gov is updated by sponsors, typically daily but sometimes with delays of weeks or months for status changes.
• No trial RESULTS extraction yet. This actor returns trial PROTOCOL data (design, enrollment, dates). Results (efficacy data, safety data, primary outcomes) are in a separate module that we don't currently parse. For most use cases (recruitment, pipeline intel, M&A) the protocol data is what you want.
• Sponsor filter is fuzzy. Searching "Pfizer" may match "Pfizer Inc", "Pfizer R&D", "Pfizer, Inc." — all three are technically separate entities in CT.gov. For precise filtering, use full legal names.
• Many trials have no investigators listed (especially industry-sponsored trials that don't disclose PIs publicly).
• Location count vs locations array: for trials with 100+ sites (some cardiovascular outcomes trials have 1,000+), enabling includeLocations: true produces very large rows. Default is off.
• API rate limit unspecified. ClinicalTrials.gov doesn't publish hard rate limits but we self-throttle to be safe.

Tips

• Track a competitor's pipeline by using sponsors: ["Moderna"] + weekly scheduled runs → diff over time to catch new Phase 1 starts and Phase 3 completions
• Find trial recruitment opportunities for your disease by using condition + statuses: ["RECRUITING"]
• Identify KOLs by using condition + includeInvestigators: true → the PIs of the biggest Phase 3 trials are the field's opinion leaders
• Monitor impending Phase 3 readouts by filtering phases: ["PHASE3"] + statuses: ["ACTIVE_NOT_RECRUITING"] + sort by primary completion date → trials wrapping up soon = near-term catalysts
• Combine with the NIH Grants Tracker: NIH funds academic research → academic trials go to ClinicalTrials.gov → triangulate which disease areas are heating up
• Combine with the SEC 13F Holdings Tracker: identify which biotech companies hedge funds just added → check their ClinicalTrials.gov pipelines
• Combine with the SEC Form 4 Insider Trades Tracker: when insiders at a biotech buy before Phase 3 readout = strong signal

Source

Uses the official ClinicalTrials.gov API v2 at https://clinicaltrials.gov/api/v2/studies. The API is:

• Free (no key, no auth)
• Comprehensive (~500,000+ registered trials worldwide)
• Authoritative (operated by NIH/NLM under FDA regulations)
• Complete (every FDA-regulated trial must register here)

Documentation: https://clinicaltrials.gov/data-api/api

License

MIT licensed. ClinicalTrials.gov data is in the public domain (US government data). You may use the extracted trial data for any purpose including commercial biotech research and pharma competitive intelligence.